Our group recently performed a post hoc analysis in advanced NSCLC patients enrolled in the multicenter, open label, randomized phase III trial TAILOR; we found that patients with KRAS/LKB1 (KL) co-mutated tumors did not show significantly worse OS when compared to patients with KRAS-mutated neoplasms [60]. Here, KRAS is linked to neoplasm.